Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Onpattro Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Onpattro (patisiran) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Medicare Part B coverage of Onpattro for adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. It specifies clinical eligibility, exclusions, documentation, dosing, and reauthorization requirements.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyOnpattro (patisiran) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation including medical records, current weight, TTR mutation status, baseline disease severity, clinical signs and symptoms, and confirmation that the patient is at least 18 years old.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18Minimum patient age
    PND ≤ IIIb or FAP 1–2Baseline disease severity
    1 yearAuthorization duration
    0.1 mgBilling unit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NoneCombination therapy

    Coverage Criteria

    Initial Therapy

    Covered when all required criteria are met and no exclusion applies.

    Initial therapy eligibility

    • Age and hereditary disease

      • Patient is at least 18 years of age.Age ≥18
      • Patient has documented hereditary transthyretin-mediated amyloidosis with a transthyretin (TTR) mutation, such as V30M.
    • Clinical manifestations and baseline severity

      • Patient has documented clinical signs and symptoms of polyneuropathy, such as motor disability or peripheral/autonomic neuropathy.
      • Baseline disease severity

        • Baseline polyneuropathy disability (PND) score is IIIb or less.PND ≤ IIIb
        • Baseline familial amyloid polyneuropathy (FAP) stage is 1 or 2.FAP Stage 1 or 2
    • Exclusions absent

      • Onpattro is not being used in combination with a TTR stabilizer, such as tafamidis, or a TTR-lowering agent, such as Amvuttra.
      • Patient has not had a liver transplant.

    Reauthorization

    Reauthorization requires documented clinical benefit compared with baseline.

    Continuation therapy: Patient demonstrates a positive clinical response to Onpattro compared with baseline, such as improved neuropathy symptoms, improved motor function, improved quality of life, or slowed disease progression.Positive response compared with baseline

    Document the response in the reauthorization request.

    Onpattro must not be used in combination with TTR stabilizers, such as tafamidis, or TTR-lowering agents, such as Amvuttra.

    Coverage is excluded when the patient has had a liver transplant.

    Coding and Clinical Thresholds

    Covered HCPCS CodeHCPCSCovered
    J0222Onpattro (patisiran); billing unit: 0.1 mg
    Baseline polyneuropathy disability (PND) score≤ IIIb
    Baseline FAP stageStage 1 or 2
    Minimum ageAt least 18 years

    Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for Onpattro (patisiran) for the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. Submit the request with the clinical documentation specified below.

    • Prescriber restrictions: None.
    • Covered indication: Polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
    Note

    Authorization Duration and Dosing

    Initial authorization and reauthorization are approved for one year. Dosing must follow FDA-approved labeling or accepted standards of medical practice.

    • Coverage duration: One year for initial authorization and reauthorization.
    • Dose approval is based on FDA-approved labeling or accepted standards of medical practice.

    Clinical Background

    Onpattro (patisiran) is a transthyretin-directed small interfering RNA therapy contained in a lipid complex injection. It is indicated for the treatment of polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis.

    Definitions

    Baseline disease severity
    PND criterionBaseline polyneuropathy disability score ≤ IIIb
    FAP criterionBaseline FAP Stage 1 or 2
    Clinical manifestationsDocumented clinical signs and symptoms such as motor disability or peripheral/autonomic neuropathy are also required for initial eligibility
    Onpattro (patisiran)
    ProductOnpattro (patisiran) lipid complex injection
    Therapy typeA transthyretin-directed small interfering RNA formulation
    Indication

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial coverage requires all of the following clinical eligibility criteria.

    Initial Onpattro eligibility

    • Age and hereditary disease documentation

      • Patient is at least 18 years of age.Age ≥18
      • Hereditary transthyretin-mediated amyloidosis is documented with a transthyretin (TTR) mutation, such as V30M.
    • Clinical polyneuropathy and baseline severity

      • Patient has documented clinical signs and symptoms of polyneuropathy, such as motor disability or peripheral/autonomic neuropathy.

    Continuation Therapy Criteria

    Continuation Criteria

    Continuation coverage requires documented benefit from Onpattro compared with the patient's baseline.

    Clinical response: Patient has a positive clinical response to Onpattro compared with baseline, demonstrated by improved neuropathy symptoms, improved motor function or quality of life, or slowed disease progression.Positive clinical response compared with baseline

    Submit documentation of the response for reauthorization.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyOnpattro (patisiran) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation including medical records, current weight, TTR mutation status, baseline disease severity, clinical signs and symptoms, and confirmation that the patient is at least 18 years old.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Provider RequirementsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy Criteria
    Documentation Required

    Required Clinical Documentation

    Provide complete clinical documentation supporting medical necessity with the authorization request, including the patient’s medical records, current weight, hereditary TTR mutation, baseline disease severity, and clinical signs and symptoms.

    • Medical records supporting the request.
    • Patient’s current weight.
    • Documentation of a transthyretin (TTR) mutation, such as V30M.
    • Baseline polyneuropathy disability (PND) score less than or equal to IIIb and/or baseline FAP Stage 1 or 2.
    • Clinical signs and symptoms, such as motor disability or peripheral/autonomic neuropathy.
    • Patient must be at least 18 years of age.
    Documentation Required

    Reauthorization Response Documentation

    For reauthorization, document a positive clinical response to Onpattro compared with baseline.

    • Examples include improved neuropathy symptoms, improved motor function, improved quality of life, or slowed disease progression.
    • Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document.
    Denial Risk

    Excluded Combination Therapy or Prior Liver Transplant

    Coverage is not available when Onpattro is used with prohibited TTR therapies or when the patient has a history of liver transplant.

    • Do not use in combination with TTR stabilizers, such as tafamidis.
    • Do not use in combination with TTR-lowering agents, such as Amvuttra.
    • Patient must not have had a liver transplant.
    Denial Risk

    Eligibility Criteria Not Met

    The request may be denied when eligibility and documentation requirements are not met, including age, hereditary TTR mutation, baseline disease severity, or documented clinical manifestations.

    • Patient must be at least 18 years of age.
    • A TTR mutation must be documented.
    • Baseline PND score must be less than or equal to IIIb and/or baseline FAP Stage must be 1 or 2.
    • Clinical signs and symptoms of hATTR polyneuropathy must be documented.
    Denial Risk

    Insufficient Response for Reauthorization

    Reauthorization may be denied when the record does not demonstrate a positive clinical response to Onpattro compared with the patient’s baseline.

    • Document response such as improved neuropathy symptoms, improved motor function, improved quality of life, or slowed disease progression.
    • Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document.
    Treatment of polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis
  1. ONE of the following baseline severity criteria

    • Baseline polyneuropathy disability (PND) score is IIIb or less.PND ≤ IIIb
    • Baseline familial amyloid polyneuropathy (FAP) stage is 1 or 2.FAP Stage 1 or 2